Nvidia earnings will show another quarter of explosive growth Nvidia earnings will show another quarter of explosive growth Nvidia earnings will show another quarter of explosive growth

Nvidia earnings will show another quarter of explosive growth

Equities 4 minutes to read
Peter Garnry

Chief Investment Strategist

Key points

  • Nvidia's strong AI-driven growth: Nvidia is expected to report a significant revenue increase of 113% YoY for FY25 Q2, driven by high demand for its AI chips (Hopper H100 and H200). Analysts anticipate Nvidia will surpass consensus estimates and possibly raise guidance for fiscal Q3, indicating continued strong momentum in the AI industry.

  • Potential political and economic impact of a "Blue Sweep": Although still considered unlikely with a 10% probability, a "Blue sweep" in the upcoming elections could lead to corporate tax hikes, negatively impacting equity markets and valuations. A Harris victory with a split Congress remains the more probable outcome, affecting fiscal stimulus extensions in 2025.

  • Growing momentum for weight-loss drugs: Eli Lilly's Zepbound study shows promising results in preventing diabetes, reinforcing the growing demand for GLP-1 weight-loss drugs. This success could lead to more government and insurance support, further boosting the obesity drug market alongside AI and defense stocks.

Nvidia earnings: The AI growth wave is not ending yet

Nvidia earnings on Wednesday is by far the most important event in global equities. Analysts expect FY25 Q2 (ending 31 July) revenue to hit $28.7bn up 113% YoY and EBITDA of $18.9bn compared to $7.4bn a year ago. Given the underlying momentum in the AI industry and the results we have seen from other companies in the AI ecosystem, we lean in direction of Nvidia beating consensus and lifting guidance for fiscal Q3 surpassing estimates. Demand is still driven by its Hopper chips H100 and H200. Besides revenue guidance the market will anxiously look for an update of its Grace Blackwell 200 chip (GB200) which was scheduled for launch in Q4 2024, but has been postponed to Q1 2025 due to a design flaw. As the chart below shows, the momentum in estimated FY25 Q4 (ending 31 January 2025) revenue is still momentum and has increased from roughly $25bn in the beginning of the year to now $35bn. Our view is that the AI wave will continue until the next GB200 investment has run its course as Google, Meta, and Microsoft will take another bet on compute power to see what it can create in terms of models and new AI applications.

Is the “Blue sweep” scenario suddenly in play?

The “Blue sweep” scenario was unthinkable just one month ago, but with the Harris momentum in polls (see chart) it is no longer a fantasy. It is important to say that this scenario still has a low probability (around 10%). What would it means if we get a “Blue sweep”? Well, it would mean that Harris and the Democratic Party could more easily implement corporate tax hikes from 21% to 28% and just shave off a significant portion of after-tax free cash flows. That would obviously be negative for valuations and equity markets. For now the most likely scenario is a Harris victory with a split Congress which has implications for the macroeconomy in 2025 as it would make extensions of fiscal stimulus much more difficult.

Source: fivethirtyeight.com

Eil Lilly Zepbound study to bolster case for weight lose drugs

Together with AI and European defence stocks the obesity theme has been strong this year as demand is extremely high for the new class of weight-loss drugs Wegovy from Novo Nordisk and Zepbound from Eli Lilly. This week, Eli Lilly announced the results of a three-year long study following patients with the risk of developing diabetes. The study showed that those patients that were on Zepbound compared to the control group had a 94% less likelihood of developing diabetes. This is more evidence that the new GLP-1 weight-loss drugs are preventive as much as curing and thus will likely add support for more government incentives, but also incentivizing insurance companies to increase coverage for these weight-loss drugs.

The week ahead: Nvidia earnings, Germany inflation, and US initial jobless claims

  • Earnings: The key earnings to watch in the week ahead are PDD (Temu, Mon), Nvidia (Wed), and Salesforce (Wed). We have already previewed Nvidia above, so our focus here is on PDD and Salesforce. Analysts expect PDD to report Q2 revenue of CNY 100bn up 91% YoY as its e-commerce platform Temu continues roll over the world with great success connecting the global consumer directly to Chinese factories. PDD is also one of the few Chinese stocks that still have a positive sentiment around it. Salesforce is expected to report FY25 Q2 (ending 31 July) revenue of $9.2bn up 7% YoY as business spending on IT applications is still under pressure from cost focus and attention on AI investments.

  • Germany inflation: Important figures as they are fundamental for the ECB’s thinking on its policy rate path. Estimates are looking for Germany’s August inflation figures to hit 2.1% YoY down from 2.3% YoY in July confirming that inflation has eased and providing flexibility for the ECB to cut its policy rate by 25 basis points (the current market pricing) at the next rate decision meeting on 12 September.

  • US initial jobless claims: Not typically a macro figure we are talking about, but the past two weeks the figure has gotten more attention, because it is a timely indicator on the US labour market. Recent Fed speeches have highlighted US labour market weakness and impacted the market’s pricing of the future Fed funds rate, but the past two weeks, the initial jobless claims have confirmed that the weak July figures were temporary and driven by hurricanes and forced the market to scale back bets on rate hikes. US initial jobless claims are out on Thursday.

Quarterly Outlook 2024 Q3

Sandcastle economics

01 / 05

  • Macro: Sandcastle economics

    Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.

    Read article
  • Bonds: What to do until inflation stabilises

    Discover strategies for managing bonds as US and European yields remain rangebound due to uncertain inflation and evolving monetary policies.

    Read article
  • Equities: Are we blowing bubbles again

    Explore key trends and opportunities in European equities and electrification theme as market dynamics echo 2021's rally.

    Read article
  • FX: Risk-on currencies to surge against havens

    Explore the outlook for USD, AUD, NZD, and EM carry trades as risk-on currencies are set to outperform in Q3 2024.

    Read article
  • Commodities: Energy and grains in focus as metals pause

    Energy and grains to shine as metals pause. Discover key trends and market drivers for commodities in Q3 2024.

    Read article
Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.